Halozyme Therapeutics, Inc. ã¯ãç±³åœãã¹ã€ã¹ãã¢ã€ã«ã©ã³ãããã«ã®ãŒãæ¥æ¬ãããã³åœéçã«ãã€ãªå»è¬åæè¡ãã©ãããã©ãŒã äŒæ¥ãšããŠäºæ¥ãå±éããŠããŸããå瀟ã®è£œåã¯ãã¢ãã¯ããŒãã«æäœããã®ä»ã®æ²»çååãå°ååãæ¶²äœãªã©ã®æ³šå°çšçç©è£œå€ã®ç®äžééãå¯èœã«ããç¹èš±ååŸæžã¿ã®çµã¿æããããã¢ã«ããããŒãŒé
µçŽ (rHuPH20) ã§ãã ENHANZE è¬ç©ééæè¡ã«åºã¥ããŠããŸããå瀟ã®å°æè£œåã«ã¯ãç®äžæ¶²æäžã容æã«ããŠæ°Žåè£çµŠãå®çŸããç®äžå°¿è·¯é 圱ã§ä»ã®æ³šå°è¬å€ã®åæ£ãšåžåãé«ããæŸå°ç·äžééæ§ç©è³ªã®ååžåãæ¹åãã rHuPH20 ã®è£œå€ã§ãã Hylenex çµã¿æãäœããããŸããå瀟ã¯ãŸããä¹³ããæ²»çè¬ Perjetaãéããžãã³ãªã³ãè
«ããã³æ
¢æ§ãªã³ãæ§çœè¡ç
(CLL) ã®æ²»çè¬ RITUXAN HYCELA ããã³ MabThera SCãCLL æ£è
çšã® RITUXAN SC ãéçºããŠããŸããå瀟ã¯ãå
ç«äžå
šçŸæ£ã®æ²»çè¬ãšã㊠HYQVIA ãéçºããŠãããããã«ãéå°çްèèºããã®æ²»çè¬ Tecentriqãå€çºæ§ç¡¬åçã®æ²»çè¬ OCREVUSãã¢ããã€ããŒã·ã¹ãããã¶ãå骚é«è
«ãå€çºæ§éªšé«è
«ã®æ£è
ã®æ²»çè¬ DARZALEXãåºåœ¢è
«çã®æ²»çè¬ Nivolumabãç®äžæ³šå°çšè£œå€ ALXN1210 ããã³ ALXN1810ãããæ°çå
Fc åå®¹äœ ARGX-113ãèªå·±å
ç«çŸæ£ã®æ²»çè¬ ARGX-117ãæ CD-73 æäœ BMS-986179 ãéçºäžã§ãããå瀟ã¯ãF. Hoffmann-La Roche, Ltd.ãHoffmann-La Roche, Inc.ãBaxalta US Inc.ãBaxalta GmbHãPfizer Inc.ãJanssen Biotech, Inc.ãAbbVie, Inc.ãEli Lilly and Company ãšææºããŠãããããªã¹ãã«ã»ãã€ã€ãŒãº ã¹ã¯ã€ã瀟ãã¢ã¬ã¯ã·ãªã³ ãã¡ãŒã ããŒã«ãã£ã³ã°ã¹ãARGENX BVBAãHorizon Therapeutics plcãåœç«ã¢ã¬ã«ã®ãŒææçç ç©¶æãåã¢ããªã«ã®ãšã€ãºç ç©¶ããã°ã©ã ã»ã³ã¿ãŒãHalozyme Therapeutics, Inc. 㯠1998 幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ãµã³ãã£ãšãŽã«æ¬ç€Ÿã眮ããŠããŸãã